AltheaDx adds Dr. Ann Kessler to the Board of Directors
"AltheaDx is very fortunate to have an industry veteran join our quest to make personalized medicine a reality”, said Dr. François Ferré, CEO of AltheaDx. “Ann's enormous experience with Hoffman - La Roche in the drug development world will immediately add an exciting dimension to both our board and management teams," said Dr. Magda Marquet, co-chairman.
AltheaDx's current Board of Directors consists of co-chairs, Magda Marquet and Francois Ferre as well as Matthew Mackowski and Deval Lashhari from Telegraph Hill Partners. Ann Kessler joins James Glavin as an Independent Director.
“This is an exciting time in drug development, as we see the convergence of diagnostics with therapeutic development. I am glad to be on the board of a world-class team that is dedicated to fulfilling their destiny,” said Dr. Ann Kessler, the newest member of the board of directors of AltheaDx.
Dr. Kessler has 27 years of full-time pharmaceutical industry experience in the United States and Europe with Hoffmann - La Roche, where she served as Director of International Project Management and was responsible for global project development decisions. She also held previous positions as Director of the Division of Exploratory Research, the Departments of Pharmacology and Chemotherapy and the Department of Biochemical Nutrition. Her managerial responsibilities in Research and Development concerned the discovery and development of novel drugs for global registration and launch in a number of therapeutic areas, including nervous system disorders. She holds 16 patents concerning pharmacological approaches to diseases.
About Althea Dx:
AltheaDx, based in San Diego, CA, is bringing theranostics into clinical use. The goal of AltheaDx is to reduce the time, risk, and cost of therapeutic development for our partners and to provide a clear path for development and commercialization of high-value companion diagnostic tests. Additional information can be found at www.altheadx.com.
|
AltheaDx Contact: |
|
Matt Gorovoy, Ph.D.
|